Miltenyi Biotec holds a dominant position in the world market for cell separation, anchored by its proprietary MACS (Magnetic Cell Separation) technology using MACS microbeads, columns and separators for magnetic cell isolation. The company's products support the development of cellular therapies and aim to make cell therapy a more viable reality for patients. Hundreds of clinical trials rely on Miltenyi products, and the company developed a subsidiary (Miltenyi Biomedicine in 2019) focusing on cell therapies, with a tandem CAR T therapy for B-cell lymphomas currently in Phase II trials.
Cyborg Score Rationale
The privately-held company maintains consistently high profitability that founder Stefan Miltenyi reinvests for growth. Miltenyi markets products in 68 countries with 29 global locations, delivering a comprehensive portfolio across core cell research and emerging cell therapy markets with regulatory momentum.
Top Insights
Comprehensive technology platform spanning sample preparation, cell separation, flow cytometry, cell culture, and molecular analysis with core applications in immunology, stem cell biology, neuroscience, and cancer
CliniMACS Cell Factories automate manufacturing of gene-modified cells for CAR T-cell therapies on a single integrated platform
Portfolio includes over 19,000 products and services in sample preparation, cell isolation, sorting, flow cytometry, cell culture, molecular analysis, and imaging
Named Competitors
Flow Cytometry Solutions — Cell analysis and sorting instruments
Cell Isolation Products — Life science research tools and antibodies
Cell Culture and Analysis — Laboratory equipment and life science products
Gene Therapy Cell Manufacturing — Cell and gene therapy development
Recent Developments
(January 2024) Partnership with Cell BioEngines for hematopoietic cell therapy program